Loading...
XHKG
1801
Market cap16bUSD
Jul 11, Last price  
80.55HKD
1D
-2.43%
1Q
68.06%
IPO
373.17%
Name

Innovent Biologics Inc

Chart & Performance

D1W1MN
P/E
P/S
12.89
EPS
Div Yield, %
Shrs. gr., 5y
6.68%
Rev. gr., 5y
55.17%
Revenues
9.42b
+51.82%
32,127,15418,538,0009,477,0001,047,525,0003,843,819,0004,269,729,0004,556,380,0006,206,070,0009,421,888,000
Net income
-95m
L-90.79%
-504,204,000-562,318,000-5,771,492,000-1,776,813,000-998,421,000-3,138,053,000-2,179,270,000-1,027,913,000-94,631,000
CFO
0k
-100.00%
-362,993,000-492,270,000-1,016,019,000-1,664,473,000-307,688,000-2,024,843,000-1,918,804,000147,810,0000
Earnings
Aug 26, 2025

Profile

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
IPO date
Oct 31, 2018
Employees
5,144
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
9,421,888
51.82%
6,206,070
36.21%
4,556,380
6.71%
Cost of revenue
10,177,760
7,885,371
7,228,463
Unusual Expense (Income)
NOPBT
(755,872)
(1,679,301)
(2,672,083)
NOPBT Margin
Operating Taxes
16,010
(116,498)
8,801
Tax Rate
NOPAT
(771,882)
(1,562,803)
(2,680,884)
Net income
(94,631)
-90.79%
(1,027,913)
-52.83%
(2,179,270)
-30.55%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,255,116
2,131,059
BB yield
-3.38%
-4.27%
Debt
Debt current
413,929
1,220,330
914,392
Long-term debt
2,430,703
2,498,796
2,439,191
Deferred revenue
883,277
Other long-term liabilities
1,698,890
1,222,764
162,305
Net debt
(8,665,004)
(8,044,592)
(5,624,226)
Cash flow
Cash from operating activities
147,810
(1,918,804)
CAPEX
(1,119,385)
(1,381,730)
Cash from investing activities
(998,662)
(1,435,185)
Cash from financing activities
2,587,257
2,892,082
FCF
(1,762,740)
(2,158,468)
(2,854,866)
Balance
Cash
7,883,740
10,969,629
8,264,594
Long term investments
3,625,896
794,089
713,215
Excess cash
11,038,542
11,453,414
8,749,990
Stockholders' equity
13,117,729
(15,767,456)
(15,917,404)
Invested Capital
6,609,120
33,138,330
30,860,428
ROIC
ROCE
EV
Common stock shares outstanding
1,627,461
1,559,637
1,490,123
Price
36.60
-14.39%
42.75
27.61%
33.50
-30.57%
Market cap
59,565,067
-10.66%
66,674,482
33.57%
49,919,127
-28.92%
EV
50,900,063
58,629,890
44,294,901
EBITDA
(755,872)
(1,294,198)
(2,352,661)
EV/EBITDA
Interest
98,624
101,698
Interest/NOPBT